Sanofi Commits Additional $625 Mn to Sanofi Ventures for Biotech & Digital Health

The evergreen fund will continue to focus on Sanofi’s strategic areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities.

Sanofi has committed an additional $625 million to Sanofi Ventures, its corporate venture capital arm, raising the fund’s total assets under management to more than $1.4 billion.

The evergreen fund will continue to focus on Sanofi’s strategic areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities.

“This new, significant capital commitment reflects our strong belief that some of the most important medical breakthroughs begin in early-stage companies. With a proven track record of strategic wins and successful exits, Sanofi Ventures has become a powerful engine for scientific progress and strategic growth,” said Paul Hudson, Chief Executive Officer at Sanofi.

“By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve people’s lives while building valuable partnerships across the healthcare ecosystem.”

Since its inception in 2012, Sanofi Ventures has deployed over $800 million across more than 70 biotech and digital health companies. The fund invests across the private company lifecycle, from seed to crossover, participates in IPOs, and maintains a globally distributed portfolio.

"The increased capital commitment enables us to deepen our role as a leading strategic investor in breakthrough science and digital innovation. Our global portfolio spans the full company lifecycle from seed-stage through IPO participation, demonstrating the long-term value we bring to both entrepreneurs and Sanofi,” said Jason P. Hafler, PhD, Managing Director at Sanofi Ventures.

“The strong performance of our fund, including three realized exits in 2024 from companies with a combined acquisition value of $3.25 billion, validates our evergreen structure and approach to identifying and supporting companies that are at the forefront of medical innovation."

Sanofi stated that the expanded commitment comes at a time when early-stage biotech funding has become more constrained. The fund aims to play a key role in advancing healthcare innovation by supporting startups developing next-generation therapies, while also strengthening Sanofi’s pipeline of future innovations.

Stay tuned for more such updates on Digital Health News